vaccine was, moreover, matched against the best saline vaccine from the standpoint of antigenic content which could be made, and its superiority was thereby abundantly demonstrated.
Salk's observations concerning the breadth of antibody response could not, however, be substantiated so far as one other virus A strain was concerned. Use of adjuvants in influenza vaccines is probably not, therefore, a solution to the problem of the immunological specificity of the inactivated influenza virus vaccine.
The rate of reactions recorded in this trial was considered to be satisfactory and to be low enough to permit exploration of a field trial using oily vaccines. At the same time, the occasional chronic reaction, often discovered only on clinical examination and not causing any grave inconvenience, appears likely to be encountered, but even the alumcontaining saline vaccine is not free from such chronic effects.
The antibody response to the emulsified vaccines appears relatively less persistent than had been anticipated. This may have been due to a deficiency of the adjuvant principle contained in the emulsions which were used. The arlacel provided by Dr. S5lk was of exceptional purity, but the efficiency of emulsions may be related in part to the content of impurities in the emulsifier. It is therefore possible that an emulsion containing more of these impurities might give a more durable antibody response. The reaction rate with such preparations might, however, be greater than with purer and therefore more easily assimilated materials. More work is clearly desirable on this and other matters connected with adjuvant vaccines.
The comparison of the antibody titres obtained with eggand mouse-adapted virus vaccines favours the latter. It is, however, difficult to be sure of the significance of the higher antibody levels with mouse-adapted virus. The differences with the two lines are not so striking as in experiments with mice. Since a number of factors such as small antigenic differences and differences in the avidity for antibody may be concerned, it seems wisest to delay interpreting these results and to compare instead the protective value of the two lines of virus. The results of trials of this nature are awaited at the moment. 1952 -3 (Report, 1953 . In these trials the attack rate of clinical influenza was 3% in 6,340 volunteers who received the virus vaccine and 4.9 % in 6,370 who received a control bacterial vaccine. It therefore seemed clear that the vaccine had a protective effect. The method of diagnosis used in these trials was entirely clinical, unaided by laboratory tests. The Committee chose the method deliberately because of the practical difficulty in obtaining and testing blood samples and throat washings from sick volunteers in trial centres scattered throughout the United Kingdom, and because it was doubted whether serological methods were valid for comparing the influenza attack rates in two groups of persons, one of which had been vaccinated with influenza virus. The Committee agreed that a small-scale trial using the same vaccines should be carried out simultaneously within the main scheme to letter was sent to all employees asking for volunteers. The scheme was discussed with the medical officer of health of Luton and with general practitioners at a meeting of the local branch of the British Medical Association. As soon as the names of volunteers were known, an explanatory letter was sent to all doctors with patients who had offered to take part.
Five hundred and five persons came forward, rather fewer than had been hoped for. All were interviewed, and 16 excluded because of a past history of tuberculosis or sensitivity to eggs, or at the request of their own doctor. Thirtyfive volunteers failed to attend for inoculation, and six of those who attended were not injected because they did not appear to be fit. In all, 458 were inoculated, but as three left the firm during the follow-up period complete records are available for only 455, 226 of whom received the trial vaccine and 229 the control.
Vaccines and Inoculation Procedure Precisely the same vaccines and inoculation procedure were used as in the main trial. The trial vaccine contained equal proportions of threefold concentrations of the F.M.1 strain and the egg-adapted Liverpool (1951) strain. Each dose of I ml. contained 9,600 haemagglutinating units of the F.M.1 strain and 12,000 units of the Liverpool (1951) strain adsorbed on to 10 mg. of aluminium phosphate. The control vaccine was a low-potency bacterial vaccine of the anticatarrhal type. Each dose of 1 ml. contained 12.5 million H. influenzae, 25 million pneumococci, and 2.5 million streptococci, in addition to 10 mg. of aluminium phosphate and merthiolate to a final concentration of 1 in 10,000.
The vaccines were given on December 8, 9, and 10 by a single deep subcutaneous injection into the left upper arm. The vaccine chosen for each volunteer was determined by use of inoculation registers, one for each sex, in which the random sequence in which the two vaccines were to be given had been set out.
Reactions
All those inoculated were seen 48 hours later by one of us and were asked about local and general reactions. These were assessed by their severity and recorded as nil, slight, and insufficient to interfere with normal activities, moderate and interfering with normal activity, or severe and causing absence from work. Most of the inoculated had a slight local reaction, but no local or general reaction was severe enough to cause absence from work. The incidence and severity of reactions still present 48 hours after inoculation are shown in Table I . At an interview during the second week in March-that is, three months after inoculation-six persons mentioned that they still had a lump at the site of injection. In each case inspection showed a round indurated subcutaneous swelling about an inch (2.5 cm.) in diameter, and in one the swelling was acutely inflamed. As this information was volunteered and not obtained by inquiry it seems possible that others may have had similar reactions.
The Follow-up Those inoculated were observed for 12 weeks, from December 15 to March 6. Each day the records department prepared a list of persons in the study who were absent from work, excluding those known to be absent for non-medical reasons. All those on the list were visited by one of us the same day and the cause of absence with details of any illness was recorded. Of 217 persons so visited 59 were not found at home, but a satisfactory explanation for 36 of these was given by another member of the household. A blood sample and throat washings were taken from any person who was thought possibly to have influenza, and from every fourth person with any other respiratory illness. A second specimen of blood was taken between 19 and 24 days later.
At the end of the trial the volunteers' attendance record cards were examined and a note was made of the date and duration of all absences of half a day or more. It was discovered that in about a quarter of the absences the volunteer's name had not appea:ed on a daily list and as a result they had not been visited during their illness.
Paired The Epidemic Cases of clinical influenza in volunteers were seen between the weeks ending January 3 and February 28, 1953. All but one of the illnesses in which serological evidence of influenza was obtained had their onset between weeks ending January 24 and February 28. The single exception was in a volunteer who was inoculated with the trial vaccine on December 9 and who developed symptoms of a common cold six days later, on December 15. Blood specimens were taken from him on December 16 and 30, and it seems probable that the rise in antibody observed was due to the vaccine rather than to natural infection. All cases diagnosed as influenza serologically were due to virus A, except one which was positive for virus C infection. After the usual fluctuations around Christmas and the New Year the number of claims for sickness benefit received by the Luton office of the Ministry of Pensions and National lnsurance began to rise in the week ended January 27, reached a peak in mid-February, and then fell away. There is thus general agreement that the epidemic period extended from the middle of January to the end of February-that is, 7 to 12 weeks after inoculation-and this is illustrated in the accompany- 
Discussion
Experience showed that, on the scale employed in this field trial, the method was practicable. It could be improved by taking steps to ensure more complete notification of absences from work, and to learn of short illnesses which occur during week-ends and so do not cause absence on a working day. Its application on a scale large enough for evaluation of a vaccine adequately would be expensive in the number of field workers required and would entail a great deal of laboratory work. The cost might be justified if greater precision was thereby obtained than in the main studies in which reliance was placed on clinical diagnosis. As the figures presented are small the difference observed between the clinical and the serological assessment cannot be accepted without further evidence, but, if confirmed, there would appear to be two possible explanations for it. If the serological method was accurate and unbiased a clinical diagnosis of influenza must have been applied to many illnesses which were not influenza. Dilution of the group of clinical influenzas with illness due to other causes probably took place, because, even in the control group, only twothirds of illnesses so diagnosed were confirmed serologically, whereas the methods used might be expected to confirm 80 to 90% of cases of virus influenza. Alternatively, serological tests may be less able to detect evidedce of influenza virus infection in vaccinated than in unvaccinated persons.
The antibody rise resulting from a single injection of influenza virus vaccine into adults is probably not a primary response, since most adults would previously have encountered a closely related antigen as the result of natural infection with the virus. The raised level of H.I. antibody observed after immunization is generally accepted as an indication of reduced susceptibility to infection; but if infection does occur in persons exhibiting this secondary response it may not be capable of provoking a further fourfold rise in antibody titre.
The level of H.I. antibody in acute-stage sera was considerably higher in the trial group than in the control group, the difference between geometric mean titres being approximately fivefold when the current 1953 virus strain was used as antigen and tenfold when the strains present in the vaccine were used. Further evidence of this difference is shown in Table III Henle, and Henle (1946) observed that a rise in antibody to soluble antigen was detected only occasionally with the batches of vaccine they were using. Kirber and Henle (1950) The main disadvantage of using clinical methods unaided by laboratory tests in the assessment of an influenza vaccine is that the proportion of illnesses correctly diagnosed as influenza is unknown, and so the degree of protection conferred cannot be determined. If the proportion of cases of true influenza to the total number of clinically diagnosed cases is low the resulting dilution may obscure the protective effect even of a good vaccine. This is particularly undesirable in the experimental stages of the development of a vaccine, when quite small differences may have considerable significance. However, it is essential that a trial method should be free from observer bias, and the clinical method in a well-designed trial has this virtue, whereas the serological method is open to question. Unless it can be shown that the chance of obtaining a detectable fourfold rise in antibody following natural infection is unrelated to the initial antibody level it would appear unwise to rely on serological methods only in any estimate of protection.
Perhaps the most important contribution which the laboratory can make to the precision of a large-scale field trial at the present time is in determining the duration and type of any influenza outbreak in communities in which the inoculated volunteers live or work. Periods in which there is no detectable virus influenza can then be excluded from the final analysis. Furthermore, knowledge of the proportion of influenzal to non-influenzal illnesses in the control group during the epidemic period would help in the interpretation of protection rates calculated from clinical diagnoses alone.
Summary
In a small-scale influenza vaccine trial undertaken mainly to determine the practicability of a trial method using both clinical and laboratory tests in the diagnosis of influenza, results led to the conclusion that the assessment of a vaccine on purely clinical grounds might understate the degree of protection, whereas one based on serological findings might exaggerate it. Possible reasons for this difference are discussed. It is concluded that, until it is shown that serological methods are able to detect cases of influenza equally well in persons who have received an influenza vaccine and in those who have not, serological diagnosis should not be the only method of diagnosis used in a vaccine field trial. In a clinical assmssment the fullest use should be made of laboratory evidence to define the epidemic period in the communities concerned and to estimate the proportion of illness in the control group due to influenza virus infection. This information would enable dilution of the figures by non-influenzal illness to be reduced and should allow a more accurate assessment of the vaccine to be made.
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